The antiproliferative effect of somatostatin analogs: Clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours

Acta Gastro-Enterologica Belgica

Volumn 72, Issue 1, 2009, Pages 54-58

  Verslype, Chris ^a   Carton, S ^b   Borbath, I ^c   Delaunoit, T ^d   Demetter, P ^e   Demolin, G ^f   Hendlisz, A ^g   Pattyn, P ^h   Pauwels, S ^c   Peeters, M ^h   Roeyen, G ⁱ   van Hootegem, Ph ^j   van Laethem, J L ^e   van Cutsem, E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Algemeen Ziekenhuis Sint Maarten   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Hospital de Jolimont   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f CHC St Joseph ^*  (Belgium)

^g JULES BORDET INSTITUTE   (Belgium)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^j Algemeen Ziekenhuis Sint Lucas Brugge   (Belgium)

more..

Author keywords

Antiproliferative effect; Neuroendocrine tumors; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; INTERFERON; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CARCINOID SYNDROME; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; GASTROENTEROPANCREATIC TUMOR; GENE EXPRESSION; GROWTH HORMONE RELEASE; GROWTH INHIBITION; HUMAN; HYPOGLYCEMIA; NEUROENDOCRINE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

CELL DIVISION; HUMANS; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SOMATOSTATIN; STOMACH NEOPLASMS;

EID: 64549123947     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. OBERG K., KVOLS L., CAPLIN M., DELLE FAVE G., DE HERDER W., RINDI G., RUSZNIEWSKI P., WOLTERING E.A., WIEDENMANN B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastro-entero-pancreatic system. Review. Ann. Oncol., 2004, 15: 966-73.
2. LAHLOU H., GUILLERMET J., HORTALA M., VERNEJOUL F., PYRONNET S., BOUSQUET C., SUSINI C. Molecular signaling of somatostatin receptors. Ann. N. Y. Acad. Sci., 2004, 1014: 121-131.
3. REICHLIN S. Secretion of somatostatin and its physiologic function. J. Lab. Clin. Med., 1987, 109: 320-326.
4. FJÄLLSKOG M.L., LUDVIGSEN E., STRIDSBERG M., OBERG K., ERIKSSON B., JANSON ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intra tumoral vessels in malignant endocrine pancreatic tumors. Med. Oncol., 2003, 1: 59-67.
5. GARCÍA DE LA TORRE N., WASS J.A., TURNER H.E. Antiangiogenic effects of somatostatin analogues. Clin. Endocrinol. (Oxf.), 2002, 57: 425-441.
6. ZATELLI M.C., TAGLIATI F., TAYLOR J.E., ROSSI R., CULLER M.D, DEGLI UBERTI E.C. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J. Clin. Endocrinol. Metab., 2001, 86: 2161-2169.
7. TAGLIATI F., ZATELLI M.C., BOTTONI A., PICCIN D., LUCHIN A., CULLER M.D., UBERTI E.C. Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology, 2006, 147: 3530-3538.
8. ROCHAIX P., DELESQUE N., ESTEVE J.P., SAINT-LAURENT N., VOIGHT J.J., VAYSSE N., SUSINI C., BUSCAIL L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther., 1999, 10: 995-1008.
9. GROZINSKY-GLASBERG S., FRANCHI G., TENG M., LEONTIOU C.A., RIBEIRO DE OLIVEIRA A. JR., DALINO P., SALAHUDDIN N., KORBONITS M., GROSSMAN A.B. Octreotide and the mTOR inhibitor RAD001 (Everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology, 2008, 87: 168-181.
10. GROZINSKY-GLASBERG S., GROSSMAN A.B., KORBONITS M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Molecular and Cellular Endocrinology, 2008, 286: 238-250.
11. FALCONI M., PLOCKINGER U., KWEKKEBOOM D.J., MANFREDI R., KORNER M., KVOLS L., PAPE U.F., RICKE J., GORETZKI P.E., WILDI S., STEINMULLER T., OBERG K., SCOAZEC J.Y. Frascati Consensus Conference; European Neuroendocrine Tumor Society. Neuroendocrinology, 2006, 84: 196-211.
12. KVOLS L.K., MOERTEL C.G., O'CONNELL M.J., SCHUTT A.J., RUBIN J., HAHN R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Eng. J. Med., 1986, 315: 663-666.
13. VINIK A.I., TSAI S.T., MOATTARI A.R., CHEUNG P., ECKHAUSER F.E., CHO K. Somatostatin analogue (SMS 201-995) in the management of gastroentero-pancreatic tumors and diarrhea syndromes. Am. J. Med., 1986, 81: 23-40.
14. OBERG K., NORHEIM I., THEODORSSON E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol., 1991, 30: 503-507.
15. WYMENGA A.N., ERIKSSON B., SALMELA P.I., JACOBSEN M.B., VAN CUTSEM E.J., FIASSE R.H., VALIMAKI M.J., RENSTRUP J., DE VRIES E.G., OBERG K.E. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol., 1999, 17: 1111.
16. RUBIN J., AJANI J., SCHIRMER W., VENOOK AP., BUKOWSKI R., POMMIER R., SALTZ L., DANDONA P., ANTHONY L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol., 1999, 17: 600-606.
17. O'TOOLE D., DUCREUX M., BOMMELAER G., WEMEAU J.L., BOUCHE O., CATUS F., BLUMBERG J., RUSZNIEWSKI P. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer, 2000, 88: 770-776.
18. VEZZOSI D., BENNET A., ROCHAIX P., COURBON F., SELVES J., PRADERE B., BUSCAIL L., SUSINI C., CARON P. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur. J. Endocrinol., 2005, 152: 757-767.
19. WERMERS R.A., FATOURECHI V., WYNNE A.G., KVOLS L.K., LLOYD R.V. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine, 1996, 75: 53-63.
20. CASADEI R., TOMASSETTI P., ROSSI C., LA DONNA M., MIGLIORI M., MARRANO D. Treatment of metastatic glucagonoma to the liver: case report and literature review. Ital. J. Gastroenterol. Hepatol., 1999, 31: 308-312.
21. O'DORISIO T.M., MEKHJIAN H.S., GAGINELLA T.S. Medical therapy of VIPomas. Endocrinol. Metab. Clin. North Am., 1989, 18: 545-556.
22. GHAFERI A.A., CHOJNACKI K.A., LONG W.D., CAMERON J.L., YEO C.J. Pancreatic VIPomas: subject review and one institutional experience. J. Gastroinrest. Surg., 2008, 12: 382-393.
23. SALTZ L., TROCHANOWSKI B., BUCKLEY M., HEFFERNAN B., NIEDZWIECKI D., TAO Y., KELSEN D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 1993, 72: 244-248.
24. MATON P.N. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J. Surg., 1993, 17: 504-510.
25. ARNOLD R., TRAUTMANN M.E., CREUTZFELDT W., BENNING R., BENNING M., NEUHAUS C., JURGENSEN R., STEIN K., SCHAFER H., BRUNS C. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastro-entero-pancreatic tumours. Gut, 1996, 38: 430-438.
26. DI BARTOLOMEO M., BAJETTA E., BUZZONI R., MARIANI L., CARNAGHI C., SOMMA L., ZILEMBO N., DI LEO A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer, 1996, 77: 402-408.
27. ERIKSSON B., RENSTRUP J., IMAM H., OBERG K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann. Oncol., 1997, 8: 1041-1044.
28. FAISS S., RATH U., MANSMANN U., CAIRD D., CLEMENS N., RIECKEN EO., WIEDENMANN B. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastro-entero-pancreatic tumors. Digestion, 1999, 60: 469-476.
29. APARICIO T., DUCREUX M., BAUDIN E., SABOURIN J.C., DE BAERE T., MITRY E., SCHLUMBERGER M., ROUGIER P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J. Cancer, 2001, 37: 1014-9.
30. SHOJAMANESH H., GIBRIL F., LOUIE A., OJEABURU J.V., BASHIR S., ABOU-SAIF A., JENSEN R.T. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer, 2002, 94: 331-343.
31. ARNOLD R., RINKE A., KLOSE K.J., MULLER H.H., WIED M., ZAMZOW K., SCHMIDT C., SCHADE-BRITTINGER C., BARTH P., MOLL R., KOLLER M., UNTERHALT M., HIDDEMANN W., SCHMIDT-LAUBER M., PAVEL M., ARNOLD C.N. Octreotide versus octreotide plus interferon-alpha in endocrine gastro-entero-pancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol., 2005, 3: 761-71.
32. PROMMEGGER R., BALE R., ENSINGER C., SAUPER T., PROFANTER C., KNOFLACH M., MONCAYO R. Gastric carcinoid type I tumour: new diagnostic and therapeutic method. Eur. J. Gastroenterol. Hepatol., 2003, 15: 705-707.
33. FYKSE V., SANDVIK A.K., QVIGSTAD G., FALKMER S.E., SYVERSEN U., WALDUM H.L. Treatment of ECL cell carcinoids with octreotide LAR. Scand. J. Gastroenterol., 2004, 39: 621-628.
34. LAMBERTS S.W., VAN DER LELY A.J., HOFLAND L.J. New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol., 2002, 146: 701-705.
35. KVOLS L., GLUSMAN J.E., HAHN E.A., WANG E., OBERG K., ANTHONY L., O'DORISIO T.M., DE HERDER W., DARBY CH., WIEDENMANN B. AND THE PASIREOTIDE CARCINOID STUDY GROUP. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J. Clin. Oncol., 2007, 25: 4558.
36. KVOLS L., OBERG K., DE HERDER W., ANTHONY L., GLUSMAN J., TRAN L., WIEDENMANN B. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J. Clin. Oncol., 2005, 23: 8024
37. FERONE D., SAVEANU A., CULLER M.D., ARVIGO M., REBORA A., GATTO F., MINUTO F., JAQUET P. Novel chimeric somatostatin analogs: facts and perspectives. Eur. J. Endocrinol., 2007, 156: 23-28.